Coripharma is a European pharmaceutical company, built on solid heritage. Our experienced team offers out-licensing and contract manufacturing services to pharmaceutical companies. Coripharma specializes in generic pharmaceutical products, solid oral dosage forms.

Coripharma

The project demanded coordinated efforts across all functional units.

A key technical achievement was the introduction of the starter pack, which features multiple strengths in a single blister. This represents the first multi‑strength blister of this type produced at Coripharma and showcases our growing capability to deliver complex packaging solutions for differentiated product presentations.

Alongside the German launch, Coripharma also supported the rollout of Apremilast in other countries, adding further presence within the European market.

Coripharma remains committed to supporting partners with high‑quality generic medicines and agile, reliable technical execution.

Coripharma is pleased to announce the successful launch of Apremilast in Germany on 17 January, immediately following patent expiry on 16 January. Delivered in close collaboration with our German partner, this patent launch represents an important milestone in Coripharma’s European commercial activities.

Coripharma and Partner Achieve Day‑1 Patent Launch of Apremilast in Germany

The comprehensive dossier for Ivacaftor is currently being finalized and is expected to be completed within the coming weeks. Coripharma has secured a Decentralized Procedure (DCP) slot with Iceland as the Reference Member State, scheduled for December 2025. 

Coripharma conducted both fed and fasted bioequivalence studies for Ivacaftor in accordance with the latest recommendations outlined in the ICH M13a guidelines. This comprehensive approach ensures the highest standards of regulatory compliance and demonstrates the company's commitment to delivering therapeutically equivalent generic alternatives. 

"The successful completion of Ivacaftor development represents our dedication to bringing high-quality generic medications to patients with rare diseases," said Thora Bjorg Magnusdottir, Director of R&D Operations at Coripharma. "Our adherence to the most current regulatory guidelines ensures that healthcare providers and patients can have confidence in the quality and efficacy of our products."

Coripharma is actively seeking partnership opportunities for the upcoming DCP submission. Pharmaceutical companies interested in collaborating on the commercialization of Ivacaftor tablets are invited to contact the company's Business Development team.

Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator used in the treatment of cystic fibrosis in patients with specific genetic mutations. The availability of generic versions of this medication will improve patient access to this essential treatment. 

Coripharma is pleased to announce the successful completion of development for Ivacaftor tablets in 75mg and 150mg strengths. The company has achieved positive results from both fed and fasted pivotal bioequivalence studies, marking a significant milestone in bringing this important cystic fibrosis treatment to the generic pharmaceutical market.

Coripharma Successfully Completes Development of Ivacaftor Tablets

Sigurdur brings twenty years of experience managing technical operations for major domestic industrial companies such as Alcoa Fjardaral, Icelandair, and most recently JBT Marel. He holds a B.Sc. degree in mechanical engineering from the University of Iceland and master's degrees in production engineering and management from the Royal Institute of Technology in Stockholm and in materials science from the Norwegian University of Science and Technology in Trondheim.

"I am very pleased to have the opportunity to lead Coripharma's newly established engineering division and look forward to building upon the excellent work that has already been done. The company is in rapid growth with exciting times ahead for further expansion. There is much to be gained in ensuring an efficient and seamless technical system as well as continuing to shape a strong culture of improvement. I am full of anticipation to tackle upcoming projects with Coripharma's powerful workforce".

Sigurdur Agust Einarsson, Director of Engineering says:

"Coripharma's operations have grown steadily, and we expect the number of tablets for export to double this year. It is therefore crucial that machinery and software efficiently support increased operations in both development and manufacturing. I am delighted to welcome Sigurdur to our strong team and I am confident that the new engineering division, under his strong leadership, will contribute to the company's continued growth and progress".

Jónína Guðmundsdóttir, CEO says:

Sigurdur Agust Einarsson has been appointed to the new position of Director of Engineering Operations at Coripharma. This new role encompasses responsibility for ensuring that all machinery, software, production systems, infrastructure, and facilities, including maintenance and continuous improvements, are in place to support rapid growth in R&D and manufacturing. Additionally, the engineering division will provide leadership in safety, health, and environmental matters. Sigurdur will also take a seat on the company's executive team.

New Director of Engineering Operations at Coripharma

Ponatinib is based on the reference product Iclusig®, used in the treatment of certain forms of leukemia. Completing this dossier showcases Coripharma’s strong technical capabilities and the effective collaboration across Coripharma’s development functions.

This milestone reflects the exceptional work and the strong cross‑functional collaboration that continues to drive Coripharma’s development pipeline forward. With the dossier now finalized, the planned submission in March 2026 positions our partners strategically for timely market access.

By advancing Ponatinib toward submission, Coripharma reinforces its commitment to expanding its oncology portfolio, supporting partners worldwide, and contributing to broader patient access to critical treatments.

Coripharma is pleased to announce the completion of its Ponatinib dossier, representing another key achievement in our ongoing commitment to advancing high‑quality generic oncology medicines.

Coripharma Finalizes Ponatinib Dossier, Targeting March 2026 Submission

About us

Services

Sustainability

Careers

Coripharma Finalizes Ponatinib Dossier, Targeting March 2026 Submission

More news

Coripharma and Partner Achieve Day‑1 Patent Launch of Apremilast in Germany

Coripharma Successfully Completes Development of Ivacaftor Tablets

New Director of Engineering Operations at Coripharma

+354 4206700